OMER

Omeros Corp. (OMER) | Rumor.io

Omeros

OMER

Attention (50-day avg)0.01%

Attention rank (50-day avg)#480

Bullish sentiment (50-day avg)94%

Price to earnings ratio11.9

Market capitalization1.4B

Earnings per share1.65

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-3.4M

Social

What share of all stock conversation is about OMER?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% -0.01	0% -0.01	0.01% +0

Sep 23

Omeros Corporation ($OMER) is expected to see a significant increase in reimbursement due to the upcoming Medicare NTAP, which could provide up to $287,079 per eligible Medicare inpatient.
The company's drug Yartemlea has been showing positive launch data, leading to a Cantor upgrade to Overweight with a price target of $22.
Omeros Corporation is expected to see a significant increase in sales, with some estimates as high as $400 million, and the company's stock price could reach $55 or higher, based on its current market capitalization.

Generated by AI

Sentiment

Of the messages about OMER that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	66.67% 0	83.33% -10.98	89.62% -5.33	87.7% -1.2
Bearish	33.33% 0	16.67% +10.98	10.38% +5.33	12.3% +1.2

Bullish· Sep 22

The company's market capitalization is still relatively low at $1.45 billion, providing a significant amount of upside potential over time.
The recent analyst upgrade from Cantor Fitzgerald to "overweight" from "neutral" with a price target suggests that the stock is poised for further growth.
The company's strong execution, launch strategy, and encouraging sales data have led some analysts to predict a move into the mid-to-high $30s by year-end, which could be within the range of the current trajectory.

Bearish· Jul 16

The company's CEO, Greg, has failed to deliver any return to shareholders in 17 years, and some users are calling for him to step down or sell the company.
The stock has been struggling to stay above its 200-day moving average (DMA) for the past two weeks, and some users are expecting more bad news.
The company's Yartemela sales are likely to be minimal, and the pipeline is empty, which is a major concern for investors.

Generated by AI

Topics

Of the messages about OMER that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	50%	4.17%	17.34%	18.84%
Announcements	0%	12.5%	12.72%	28.47%
Analysts	50%	79.17%	53.18%	22.88%
Earnings	0%	4.17%	16.18%	4.13%
Controversies	0%	0%	0.58%	1.59%
Macro	0%	0%	0%	24.09%

Earnings· Aug 9

Omeros Corporation (OMER) reported a loss of $0.70 in Q2 2018, missing the consensus estimate of ($0.66).
The company's revenue for Q2 2018 was $1.66 million, missing the Estimize revenue consensus by $0.68 million.
OMER stock gained 2.30% after the company reported its Q2 2018 financial results.

Analysts· Aug 18

WBB Securities raised Omeros' price target to $75, previously at $60, and reiterated a "buy" rating.
Wedbush Securities raised Omeros' price target to $70 and reiterated an "outperform" rating.
Omeros received a "buy" rating and $60 price target from WBB Securities, and a "strong-buy" rating and $75 price target from the same firm.

Announcements· Jan 14

Omeros Corporation's MASP-2 inhibitor, narsoplimab, is being integrated into Novo Nordisk's rare disease pipeline.
Novo Nordisk has acquired global rights to zaltenibart, a MASP-3 inhibitor from Omeros Corporation, for $2.1 billion.
Omeros' lead asset, narsoplimab, targets MASP-2, while zaltenibart targets MASP-3, positioning the company as a key player in complement-mediated diseases.

Technical Analysis· Dec 24

$OMER's recent price action shows a significant volume spike, with 23.96M shares traded, and a price surge from $8.75 to $15.36.
A bullish pennant appears to be in progress on the 15-second chart, with a potential target of ~$22, if validated.
Breaking $16 is the next major resistance for $OMER, but it needs to break 15.5 first, with smart moves waiting for a lower H% before considering entry.

Generated by AI

Community

Of the messages about OMER, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	63.16%	73.99%	88.02%	64.36%
Newcomers	36.84%	26.01%	11.98%	35.64%

Regulars· Sep 22

The regulars are confident in Dr. Greg Demopulos' leadership and the company's potential, with one stating it's "TIME IN THE MARKET, not TIMING THE MARKET" and another calling it a "parabolic growth stage" with "only just begun."
The company's YARTEMLEA (narsoplimab) treatment has been granted NTAP (National Average Sales Price) status by CMS, which will start on October 1, 2026, and is expected to have a significant impact on revenue.
The regulars are celebrating the stock's recent price action, with one calling it a "great and sustainable final moonshot" and another stating that the market cap is still relatively low at $1.45 billion, with significant room for growth.

Newcomers· Aug 14

Analysts expect $5 EPS per share in 2030, making the stock potentially worth $100 with a low PE ratio.
Institutional ownership is low at 43%, which could lead to increased price stability if more institutions invest, and retail investors may drive the stock's price movements.
The company's treatment costs up to $1 million per patient, and a single vial costs $36,000, which could impact the stock's price if the drug gains approval.

Generated by AI

News

Omeros VP finance David Borges sells $419,000 in shares

5d agoInvesting.com

Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst - Omeros (NASDAQ:OMER)

Cantor upgrades Omeros to Overweight with a $22 price forecast following strong Yartemlea sales and Medicare reimbursement momentum.

7d agoBenzinga

Also Discussed

Investors talking about OMER also mention

#	Name	Attention
1	NextNav Inc.NN	0%+0
2	Ocular Therapeutix, Inc.OCUL	0.02%-0.04
3	Rockwell Medical Inc.RMTI	0%new
4	BDSI - BioDelivery Sciences International, Inc.	——
5	TG Therapeutics Inc.TGTX	0.01%+0
6	Exelixis Inc.EXEL	0%-0.03
7	RDUS - Radius Recycling, Inc.	——
8	Akari Therapeutics Plc ADRAKTX	0%0
9	MACK - Merrimack Pharmaceuticals, Inc.	——
10	Arrowhead Pharmaceuticals, Inc.ARWR	0%+0

Omeros Corp.

Healthcare
Biotechnology

Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. The company concentrates on immunologic and complement-mediated diseases, along with selected orphan and rare indications affecting inflammation, coagulopathies, and central nervous system disorders. Its portfolio includes commercial and development-stage programs designed to address unmet medical needs across hematology, nephrology, immunology, oncology, and addiction-related conditions. Omeros also works on targeted therapeutics that modulate the complement pathway, a key part of the immune system involved in several serious diseases. Headquartered in Seattle, Washington, Omeros Corp. plays a specialized role in the biotechnology market by advancing differentiated therapies from research through commercialization.

Website

Location

The Omeros Building

Seattle, WA, 98119

United States

Social

What share of all stock conversation is about OMER?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% -0.01	0% -0.01	0.01% +0

Sep 23

Omeros Corporation ($OMER) is expected to see a significant increase in reimbursement due to the upcoming Medicare NTAP, which could provide up to $287,079 per eligible Medicare inpatient.
The company's drug Yartemlea has been showing positive launch data, leading to a Cantor upgrade to Overweight with a price target of $22.
Omeros Corporation is expected to see a significant increase in sales, with some estimates as high as $400 million, and the company's stock price could reach $55 or higher, based on its current market capitalization.

Generated by AI

Sentiment

Of the messages about OMER that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	66.67% 0	83.33% -10.98	89.62% -5.33	87.7% -1.2
Bearish	33.33% 0	16.67% +10.98	10.38% +5.33	12.3% +1.2

Bullish· Sep 22

The company's market capitalization is still relatively low at $1.45 billion, providing a significant amount of upside potential over time.
The recent analyst upgrade from Cantor Fitzgerald to "overweight" from "neutral" with a price target suggests that the stock is poised for further growth.
The company's strong execution, launch strategy, and encouraging sales data have led some analysts to predict a move into the mid-to-high $30s by year-end, which could be within the range of the current trajectory.

Bearish· Jul 16

The company's CEO, Greg, has failed to deliver any return to shareholders in 17 years, and some users are calling for him to step down or sell the company.
The stock has been struggling to stay above its 200-day moving average (DMA) for the past two weeks, and some users are expecting more bad news.
The company's Yartemela sales are likely to be minimal, and the pipeline is empty, which is a major concern for investors.

Generated by AI

Topics

Of the messages about OMER that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	50%	4.17%	17.34%	18.84%
Announcements	0%	12.5%	12.72%	28.47%
Analysts	50%	79.17%	53.18%	22.88%
Earnings	0%	4.17%	16.18%	4.13%
Controversies	0%	0%	0.58%	1.59%
Macro	0%	0%	0%	24.09%

Earnings· Aug 9

Omeros Corporation (OMER) reported a loss of $0.70 in Q2 2018, missing the consensus estimate of ($0.66).
The company's revenue for Q2 2018 was $1.66 million, missing the Estimize revenue consensus by $0.68 million.
OMER stock gained 2.30% after the company reported its Q2 2018 financial results.

Analysts· Aug 18

WBB Securities raised Omeros' price target to $75, previously at $60, and reiterated a "buy" rating.
Wedbush Securities raised Omeros' price target to $70 and reiterated an "outperform" rating.
Omeros received a "buy" rating and $60 price target from WBB Securities, and a "strong-buy" rating and $75 price target from the same firm.

Announcements· Jan 14

Omeros Corporation's MASP-2 inhibitor, narsoplimab, is being integrated into Novo Nordisk's rare disease pipeline.
Novo Nordisk has acquired global rights to zaltenibart, a MASP-3 inhibitor from Omeros Corporation, for $2.1 billion.
Omeros' lead asset, narsoplimab, targets MASP-2, while zaltenibart targets MASP-3, positioning the company as a key player in complement-mediated diseases.

Technical Analysis· Dec 24

$OMER's recent price action shows a significant volume spike, with 23.96M shares traded, and a price surge from $8.75 to $15.36.
A bullish pennant appears to be in progress on the 15-second chart, with a potential target of ~$22, if validated.
Breaking $16 is the next major resistance for $OMER, but it needs to break 15.5 first, with smart moves waiting for a lower H% before considering entry.

Generated by AI

Community

Of the messages about OMER, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	63.16%	73.99%	88.02%	64.36%
Newcomers	36.84%	26.01%	11.98%	35.64%

Regulars· Sep 22

The regulars are confident in Dr. Greg Demopulos' leadership and the company's potential, with one stating it's "TIME IN THE MARKET, not TIMING THE MARKET" and another calling it a "parabolic growth stage" with "only just begun."
The company's YARTEMLEA (narsoplimab) treatment has been granted NTAP (National Average Sales Price) status by CMS, which will start on October 1, 2026, and is expected to have a significant impact on revenue.
The regulars are celebrating the stock's recent price action, with one calling it a "great and sustainable final moonshot" and another stating that the market cap is still relatively low at $1.45 billion, with significant room for growth.

Newcomers· Aug 14

Analysts expect $5 EPS per share in 2030, making the stock potentially worth $100 with a low PE ratio.
Institutional ownership is low at 43%, which could lead to increased price stability if more institutions invest, and retail investors may drive the stock's price movements.
The company's treatment costs up to $1 million per patient, and a single vial costs $36,000, which could impact the stock's price if the drug gains approval.

Generated by AI

Omeros

Social

Sep 23

Bullish· Sep 22

Bearish· Jul 16

Earnings· Aug 9

Analysts· Aug 18

Announcements· Jan 14

Technical Analysis· Dec 24

Regulars· Sep 22

Newcomers· Aug 14

Omeros VP finance David Borges sells $419,000 in shares

Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst - Omeros (NASDAQ:OMER)

Omeros stock upgraded at Cantor Fitzgerald (OMER:NASDAQ)

Cantor Fitzgerald upgrades Omeros stock rating on Yartemlea launch

Omeros VP, finance & CAO David Borges sells $206,804 in shares

Omeros Insider Sold Shares Worth $929,668, According to a Recent SEC Filing

Also Discussed

Omeros Corp.

Company Information

Location

Omeros VP finance David Borges sells $419,000 in shares

Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst - Omeros (NASDAQ:OMER)

Omeros stock upgraded at Cantor Fitzgerald (OMER:NASDAQ)

Cantor Fitzgerald upgrades Omeros stock rating on Yartemlea launch

Omeros VP, finance & CAO David Borges sells $206,804 in shares

Omeros Insider Sold Shares Worth $929,668, According to a Recent SEC Filing

Also Discussed

Social

Sep 23

Bullish· Sep 22

Bearish· Jul 16

Earnings· Aug 9

Analysts· Aug 18

Announcements· Jan 14

Technical Analysis· Dec 24

Regulars· Sep 22

Newcomers· Aug 14